Different Induction Response Criteria Do Not Influence 1-Year Response and Remission Rates of Ustekinumab 90 Mg Q8w in Phase III Program

Dominik Naessens(Janssen (Belgium)), C Gasink, Jewel Johanns(Johnson & Johnson (United States))
The American Journal of Gastroenterology
October 1, 2016
10.14309/00000434-201610001-00665
Cited by 1

Related Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
|Gastroenterology|2013|938